Literature DB >> 33043588

EP300-related Rubinstein-Taybi syndrome: Highlighted rare phenotypic findings and a genotype-phenotype meta-analysis of 74 patients.

Jennifer L Cohen1,2,3, Samantha A Schrier Vergano4, Sarah Mazzola5, Alanna Strong1,2, Beth Keena1, Carey McDougall1, Alyssa Ritter1, Dong Li1, Emma C Bedoukian1, Leah W Burke6, Amber Hoffman7,8, Victoria Zurcher5, Ian D Krantz1,2, Kosuke Izumi1,2, Elizabeth Bhoj1,2, Elaine H Zackai1,2, Matthew A Deardorff1,2,9.   

Abstract

Pathogenic variants in the homologous and highly conserved genes-CREBBP and EP300-are causal for Rubinstein-Taybi syndrome (RSTS). CREBBP and EP300 encode histone acetyltransferases (HAT) that act as transcriptional co-activators, and their haploinsufficiency causes the pathology characteristic of RSTS by interfering with global transcriptional regulation. Though generally a well-characterized syndrome, there is a clear phenotypic spectrum; rare associations have emerged with increasing diagnosis that is critical for comprehensive understanding of this rare syndrome. We present 12 unreported patients with RSTS found to have EP300 variants discovered through gene sequencing and chromosomal microarray. Our cohort highlights rare phenotypic features associated with EP300 variants, including imperforate anus, retained fetal finger pads, and spina bifida occulta. Our findings support the previously noted prevalence of pregnancy-related hypertension/preeclampsia seen with this disease. We additionally performed a meta-analysis on our newly reported 12 patients and 62 of the 90 previously reported patients. We demonstrated no statistically significant correlation between phenotype severity (within the domains of intellectual disability and major organ involvement, as defined in our Methods section) and variant location and type; this is in contrast to the conclusions of some smaller studies and highlights the importance of large patient cohorts in characterization of this rare disease.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  HAT domain; Rubinstein-Taybi syndrome; genotype-phenotype correlation

Mesh:

Substances:

Year:  2020        PMID: 33043588     DOI: 10.1002/ajmg.a.61883

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  5 in total

1.  Putative Roles of SETBP1 Dosage on the SET Oncogene to Affect Brain Development.

Authors:  Lilit Antonyan; Carl Ernst
Journal:  Front Neurosci       Date:  2022-05-24       Impact factor: 5.152

2.  Hyperinsulinism in an individual with an EP300 variant of Rubinstein-Taybi syndrome.

Authors:  K Taylor Wild; Tomoki T Nomakuchi; Sarah E Sheppard; Karla F Leavens; Diva D De León; Elaine H Zackai
Journal:  Am J Med Genet A       Date:  2021-01-14       Impact factor: 2.802

Review 3.  Epigenetic disorders: Lessons from the animals-animal models in chromatinopathies.

Authors:  Elisabetta Di Fede; Paolo Grazioli; Antonella Lettieri; Chiara Parodi; Silvia Castiglioni; Esi Taci; Elisa Adele Colombo; Silvia Ancona; Alberto Priori; Cristina Gervasini; Valentina Massa
Journal:  Front Cell Dev Biol       Date:  2022-09-26

Review 4.  Rubinstein-Taybi Syndrome: A Model of Epigenetic Disorder.

Authors:  Julien Van Gils; Frederique Magdinier; Patricia Fergelot; Didier Lacombe
Journal:  Genes (Basel)       Date:  2021-06-24       Impact factor: 4.096

5.  Genetic and clinical heterogeneity in Korean patients with Rubinstein-Taybi syndrome.

Authors:  Naye Choi; Hwa Young Kim; Byung Chan Lim; Jong-Hee Chae; Soo Yeon Kim; Jung Min Ko
Journal:  Mol Genet Genomic Med       Date:  2021-08-24       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.